Neuronal PAD4 expression and protein citrullination: Possible role in production of autoantibodies associated with neurodegenerative disease

Journal of Autoimmunity

Volumn 38, Issue 4, 2012, Pages 369-380

  Acharya, Nimish K ^a,b   Nagele, Eric P ^a   Han, Min ^a,b   Coretti, Nicholas J ^b   DeMarshall, Cassandra ^b   Kosciuk, Mary C ^a   Boulos, Paul A ^a   Nagele, Robert G ^a  

^a UMDNJ School of Osteopathic Medicine   (United States)

^b UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

Alzheimer's disease (AD); Autoantibody; Autoimmunity; Citrullination; Citrulline; Deimination; Neurodegenerative disease; Peptidyl arginine deiminase (PAD)

Indexed keywords

ANTIGEN; AUTOANTIBODY; BRAIN PROTEIN; PENTATRICOPEPTIDE REPEAT DOMAIN2 PROTEIN; PROTEIN ARGININE DEIMINASE; PROTEIN ARGININE DEIMINASE 2; PROTEIN ARGININE DEIMINASE 4; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ANTIBODY PRODUCTION; ARTICLE; BRAIN CIRCULATION; BRAIN REGION; CONTROLLED STUDY; DEGENERATIVE DISEASE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNE SYSTEM; INTERSTITIUM; LYMPH FLOW; PRIORITY JOURNAL; PROTEIN CITRULLINATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN PROCESSING;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ASTROCYTES; AUTOANTIBODIES; BRAIN; CITRULLINE; HUMANS; HYDROLASES; ISOENZYMES; MIDDLE AGED; MITOCHONDRIAL PROTEINS; NEURODEGENERATIVE DISEASES; NEURONS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT;

EID: 84861198405     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2012.03.004     Document Type: Article

References (67)

1. Anzilotti C., Pratesi F., Tommasi C., Migliorini P. Peptidylarginine deiminase 4 and citrullination in health and disease. Autoimmun Rev 2010, 9:158-160.
2. Gyorgy B., Toth E., Tarcsa E., Falus A., Buzas E.I. Citrullination: a posttranslational modification in health and disease. Int J Biochem Cell Biol 2006, 38:1662-1677.
3. Yamada R., Suzuki A., Chang X., Yamamoto K. Citrullinated proteins in rheumatoid arthritis. Front Biosci 2005, 10:54-64.
4. Luban S., Li Z.G. Citrullinated peptide and its relevance to rheumatoid arthritis: an update. Int J Rheum Dis 2010, 13:284-287.
5. Jones J.E., Causey C.P., Knuckley B., Slack-Noyes J.L., Thompson P.R. Protein arginine deiminase 4 (PAD4): current understanding and future therapeutic potential. Curr Opin Drug Discov Dev 2009, 12:616-627.
6. Graus F., Saiz A., Dalmau J. Antibodies and neuronal autoimmune disorders of the CNS. J Neurol 2010, 257:509-517.
7. Moscarello M.A., Mastronardi F.G., Wood D.D. The role of citrullinated proteins suggests a novel mechanism in the pathogenesis of multiple sclerosis. Neurochem Res 2007, 32:251-256.
8. Wegner N., Lundberg K., Kinloch A., Fisher B., Malmstrom V., Feldmann M., et al. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol Rev 2010, 233:34-54.
9. Yamada R. Peptidylarginine deiminase type 4, anticitrullinated peptide antibodies, and rheumatoid arthritis. Autoimmun Rev 2005, 4:201-206.
10. Alivernini S., Fedele A.L., Cuoghi I., Tolusso B., Ferraccioli G. Citrullination: the loss of tolerance and development of autoimmunity in rheumatoid arthritis. Reumatismo 2008, 60:85-94.
11. Kinloch A., Lundberg K., Wait R., Wegner N., Lim N.H., Zendman A.J., et al. Synovial fluid is a site of citrullination of autoantigens in inflammatory arthritis. Arthritis Rheum 2008, 58:2287-2295.
12. Kinloch A.J., Lundberg K.E., Moyes D., Venables P.J. Pathogenic role of antibodies to citrullinated proteins in rheumatoid arthritis. Expert Rev Clin Immunol 2006, 2:365-375.
13. Yasojima K., Schwab C., McGeer E.G., McGeer P.L. Up-regulated production and activation of the complement system in Alzheimer's disease brain. Am J Pathol 1999, 154:927-936.
14. Nijenhuis S., Zendman A.J., Vossenaar E.R., Pruijn G.J., vanVenrooij W.J. Autoantibodies to citrullinated proteins in rheumatoid arthritis: clinical performance and biochemical aspects of an RA-specific marker. Clin Chim Acta 2004, 350:17-34.
15. Vossenaar E.R., Zendman A.J., Van Venrooij W.J. Citrullination, a possible functional link between susceptibility genes and rheumatoid arthritis. Arthritis Res Ther 2004, 6:1-5.
16. Harauz G., Musse A.A. A tale of two citrullines-structural and functional aspects of myelin basic protein deimination in health and disease. Neurochem Res 2007, 32:137-158.
17. Ishida-Yamamoto A., Senshu T., Takahashi H., Akiyama K., Nomura K., Iizuka H. Decreased deiminated keratin K1 in psoriatic hyperproliferative epidermis. J Invest Dermatol 2000, 114:701-705.
18. Jang B., Jin J.K., Jeon Y.C., Cho H.J., Ishigami A., Choi K.C., et al. Involvement of peptidylarginine deiminase-mediated post-translational citrullination in pathogenesis of sporadic Creutzfeldt-Jakob disease. Acta Neuropathol 2010, 119:199-210.
19. Schwartz M., Ziv Y. Immunity to self and self-maintenance: a unified theory of brain pathologies. Trends Immunol 2008, 29:211-219.
20. Trouw L.A., Nielsen H.M., Minthon L., Londos E., Landberg G., Veerhuis R., et al. C4b-binding protein in Alzheimer's disease: binding to Abeta1-42 and to dead cells. Mol Immunol 2008, 45:3649-3660.
21. Wood D.D., Ackerley C.A., Brand B., Zhang L., Raijmakers R., Mastronardi F.G., et al. Myelin localization of peptidylarginine deiminases 2 and 4: comparison of PAD2 and PAD4 activities. Lab Invest 2008, 88:354-364.
22. Ishigami A., Ohsawa T., Hiratsuka M., Taguchi H., Kobayashi S., Saito Y., et al. Abnormal accumulation of citrullinated proteins catalyzed by peptidylarginine deiminase in hippocampal extracts from patients with Alzheimer's disease. J Neurosci Res 2005, 80:120-128.
23. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
24. Dickson D.W. The pathogenesis of senile plaques. J Neuropathol Exp Neurol 1997, 56:321-339.
25. Grundke-Iqbal I., Iqbal K., Tung Y.C., Quinlan M., Wisniewski H.M., Binder L.I. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A 1986, 83:4913-4917.
26. Romano A.D., Serviddio G., de Matthaeis A., Bellanti F., Vendemiale G. Oxidative stress and aging. J Nephrol 2010, 23(Suppl. 15):S29-S36.
27. Verkhratsky A., Olabarria M., Noristani H.N., Yeh C.Y., Rodriguez J.J. Astrocytes in Alzheimer's disease. Neurotherapeutics: J Am Soc Exp Neurother 2010, 7:399-412.
28. Levin E.C., Acharya N.K., Han M., Zavareh S.B., Sedeyn J.C., Venkataraman V., et al. Brain-reactive autoantibodies are nearly ubiquitous in human sera and may be linked to pathology in the context of blood-brain barrier breakdown. Brain Res 2010, 1345:221-232.
29. Nagele R.G., Clifford P.M., Siu G., Levin E.C., Acharya N.K., Han M., et al. Brain-reactive autoantibodies prevalent in human sera increase intraneuronal amyloid-beta1-42 deposition. J Alzheimers Dis 2011, 25:605-622.
30. Nagele E., Han M., Demarshall C., Belinka B., Nagele R. Diagnosis of Alzheimer's disease based on disease-specific autoantibody profiles in human sera. PLoS One 2011, 6:e23112.
31. Han M., Nagele E., Demarshall C., Acharya N., Nagele R. Diagnosis of Parkinson's disease based on disease-specific autoantibody profiles in human sera. PLoS One 2012, 7:e32383.
32. Brun A., Gustafson L. Distribution of cerebral degeneration in Alzheimer's disease. A clinico-pathological study. Archiv fur Psychiatrie und Nervenkrankheiten 1976, 223:15-33.
33. Mormino E.C., Kluth J.T., Madison C.M., Rabinovici G.D., Baker S.L., Miller B.L., et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009, 132:1310-1323.
34. Sabuncu M.R., Desikan R.S., Sepulcre J., Yeo B.T., Liu H., Schmansky N.J., et al. The dynamics of cortical and hippocampal atrophy in Alzheimer disease. Arch Neurol 2011, 68:1040-1048.
35. Tarcsa E., Marekov L.N., Mei G., Melino G., Lee S.C., Steinert P.M. Protein unfolding by peptidylarginine deiminase. Substrate specificity and structural relationships of the natural substrates trichohyalin and filaggrin. J Biol Chem 1996, 271:30709-30716.
36. Vossenaar E.R., Zendman A.J., van Venrooij W.J., Pruijn G.J. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays 2003, 25:1106-1118.
37. Ishigami A., Maruyama N. Importance of research on peptidylarginine deiminase and citrullinated proteins in age-related disease. Geriatr Gerontol Int 2010, 10(Suppl. 1):S53-S58.
38. Koval L., Lykhmus O., Kalashnyk O., Bachinskaya N., Kravtsova G., Soldatkina M., et al. The presence and origin of autoantibodies against alpha4 and alpha7 nicotinic acetylcholine receptors in the human blood: possible relevance to Alzheimer's pathology. J Alzheimers Dis 2011, 25:747-761.
39. Chang X., Han J., Pang L., Zhao Y., Yang Y., Shen Z. Increased PADI4 expression in blood and tissues of patients with malignant tumors. BMC Cancer 2009, 9:40.
40. Proost P., Loos T., Mortier A., Schutyser E., Gouwy M., Noppen S., et al. Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation. J Exp Med 2008, 205:2085-2097.
41. Mortier A., Loos T., Gouwy M., Ronsse I., Van Damme J., Proost P. Posttranslational modification of the NH2-terminal region of CXCL5 by proteases or peptidylarginine deiminases (PAD) differently affects its biological activity. J Biol Chem 2010, 285:29750-29759.
42. Struyf S., Noppen S., Loos T., Mortier A., Gouwy M., Verbeke H., et al. Citrullination of CXCL12 differentially reduces CXCR4 and CXCR7 binding with loss of inflammatory and anti-HIV-1 activity via CXCR4. J Immunol 2009, 182:666-674.
43. Nakayama-Hamada M., Suzuki A., Furukawa H., Yamada R., Yamamoto K. Citrullinated fibrinogen inhibits thrombin-catalysed fibrin polymerization. J Biochem 2008, 144:393-398.
44. Okumura N., Haneishi A., Terasawa F. Citrullinated fibrinogen shows defects in FPA and FPB release and fibrin polymerization catalyzed by thrombin. Clin Chim Acta 2009, 401:119-123.
45. Cuthbert G.L., Daujat S., Snowden A.W., Erdjument-Bromage H., Hagiwara T., Yamada M., et al. Histone deimination antagonizes arginine methylation. Cell 2004, 118:545-553.
46. Wang Y., Wysocka J., Sayegh J., Lee Y.H., Perlin J.R., Leonelli L., et al. Human PAD4 regulates histone arginine methylation levels via demethylimination. Science 2004, 306:279-283.
47. Anderton S.M. Post-translational modifications of self antigens: implications for autoimmunity. Curr Opin Immunol 2004, 16:753-758.
48. Doyle H.A., Mamula M.J. Autoantigenesis: the evolution of protein modifications in autoimmune disease. Curr Opin Immunol 2011.
49. Adamus G., Brown L., Schiffman J., Iannaccone A. Diversity in autoimmunity against retinal, neuronal, and axonal antigens in acquired neuro-retinopathy. J Ophthalmic Inflamm Infect 2011, 1:111-121.
50. Flanagan E.P., Caselli R.J. Autoimmune encephalopathy. Semin Neurol 2011, 31:144-157.
51. Hung T.Y., Foo N.H., Lai M.C. Anti-N-methyl-d-aspartate receptor encephalitis. Pediatr Neonatol 2011, 52:361-364.
52. Vernino S., Geschwind M., Boeve B. Autoimmune encephalopathies. Neurologist 2007, 13:140-147.
53. Liao L., Cheng D., Wang J., Duong D.M., Losik T.G., Gearing M., et al. Proteomic characterization of postmortem amyloid plaques isolated by laser capture microdissection. J Biol Chem 2004, 279:37061-37068.
54. Diamond B., Huerta P.T., Mina-Osorio P., Kowal C., Volpe B.T. Losing your nerves? Maybe it's the antibodies. Nat Rev Immunol 2009, 9:449-456.
55. Gordon N. Sydenham's chorea, and its complications affecting the nervous system. Brain Dev 2009, 31:11-14.
56. Hoekstra P.J., Minderaa R.B. Tic disorders and obsessive-compulsive disorder: is autoimmunity involved?. Int Rev Psychiatry 2005, 17:497-502.
57. Kirvan C.A., Swedo S.E., Snider L.A., Cunningham M.W. Antibody-mediated neuronal cell signaling in behavior and movement disorders. J Neuroimmunol 2006, 179:173-179.
58. Mocellin R., Walterfang M., Velakoulis D. Hashimoto's encephalopathy: epidemiology, pathogenesis and management. CNS Drugs 2007, 21:799-811.
59. Ainiala H., Loukkola J., Peltola J., Korpela M., Hietaharju A. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 2001, 57:496-500.
60. Diamond B., Kowal C., Huerta P.T., Aranow C., Mackay M., DeGiorgio L.A., et al. Immunity and acquired alterations in cognition and emotion: lessons from SLE. Adv Immunol 2006, 89:289-320.
61. Kowal C., DeGiorgio L.A., Nakaoka T., Hetherington H., Huerta P.T., Diamond B., et al. Cognition and immunity; antibody impairs memory. Immunity 2004, 21:179-188.
62. Loukkola J., Laine M., Ainiala H., Peltola J., Metsanoja R., Auvinen A., et al. Cognitive impairment in systemic lupus erythematosus and neuropsychiatric systemic lupus erythematosus: a population-based neuropsychological study. J Clin Exp Neuropsychol 2003, 25:145-151.
63. DeGiorgio L.A., Konstantinov K.N., Lee S.C., Hardin J.A., Volpe B.T., Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med 2001, 7:1189-1193.
64. Lennon V.A., Ermilov L.G., Szurszewski J.H., Vernino S. Immunization with neuronal nicotinic acetylcholine receptor induces neurological autoimmune disease. J Clin Invest 2003, 111:907-913.
65. McKeon A., Lennon V.A., Lachance D.H., Fealey R.D., Pittock S.J. Ganglionic acetylcholine receptor autoantibody: oncological, neurological, and serological accompaniments. Arch Neurol 2009, 66:735-741.
66. Vernino S., Hopkins S., Wang Z. Autonomic ganglia, acetylcholine receptor antibodies, and autoimmune ganglionopathy. Auton Neurosci 2009, 146:3-7.
67. Clifford P.M., Zarrabi S., Siu G., Kinsler K.J., Kosciuk M.C., Venkataraman V., et al. Abeta peptides can enter the brain through a defective blood-brain barrier and bind selectively to neurons. Brain Res 2007, 1142:223-236.